“Omeros announced that it has submitted a pediatric investigational plan (PIP) to the EMA for the use of OMS721 in hematopoietic stem cell transplant- associated thrombotic microangiopathy (HSCT-TMA). In parallel, the company is also undertaking plans to submit a pediatric study plan (PSP) for submission to the FDA.”
According to TipRanks.com, McCarthy is a 1-star analyst with an average return of -1.8% and a 34.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Omeros Corp with a $33 average price target, a 144.1% upside from current levels. In a report issued on December 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $34 price target.
Based on Omeros Corp’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $39.47 million. In comparison, last year the company had a GAAP net loss of $7.48 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omeros Corp. operates as a biopharmaceutical company specializes in discovery, development, and commercializes of both small-molecule and protein therapeutics for large -market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system.
Read More on OMER: